January 2026
Cannabis
What January 2026's 12 new studies found, synthesized from the papers below. All Cannabis research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Cannabis, marijuana, THC, tetrahydrocannabinol, then ranked by relevance.
Research published in January 2026 indicates that cannabis (THC) acutely enhances reward-related brain activity and can impair cognition, with chronic use linked to reduced brain structure and function. However, cannabis-based medicines show no clear evidence of providing clinically meaningful pain relief for chronic neuropathic pain, and any small benefits are accompanied by increased adverse events. The evidence is mixed, with many studies being small, animal-based, or observational, and a key ongoing trial has not yet reported results.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Δ 9 -Tetrahydrocannabinol-induced enhancement of reward responsivity via mesocorticolimbic modulation in squirrel monkeys. 2026 | experimental study with within-subject design | 4 | Supports | THC selectively enhanced behavioral and neural responses to reward-predicting cues by amplifying mesocorticolimbic activity. |
| Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use 2026 | review | Unclear | Psychological context ('set') is more strongly associated with psychedelic outcomes than substance type alone. | |
| Cannabis-based medicines for chronic neuropathic pain in adults. 2026 | systematic review with meta-analysis | 2187 | No effect | Cannabis-based medicines showed no clear evidence of providing clinically meaningful pain relief (≥50% reduction) compared with placebo, with low to very low certainty evidence. |
| Detection of Δ9-Tetrahydrocannabinol Impairment Using Resting-State Functional Near-Infrared Spectroscopy: A Randomized Clinical Trial. 2026 | double-blind, randomized, crossover trial | 183 | Supports | Resting-state fNIRS detected THC-induced impairment with 90% accuracy and a 5% false-positive rate, significantly outperforming field sobriety tests. |
| THC induced similar physiological effects on HIV transgenic rats and their controls without affecting HIV-induced deficits in effortful motivation. 2026 | experimental study | 275 | Mixed | THC (3 mg/kg) reduced nociception, body temperature, locomotor and exploratory activity, and acute motivation across genotypes, but chronic treatment did not affect motivation. |
| Addressing US Demand for Psychedelic Medicines in the Face of Scientific Uncertainty. 2026 | review | Unclear | Policymakers should balance evidence, patient safeguards, and speed by supporting research, avoiding hindrances, improving pre-approval access, and preventing political FDA approvals. | |
| Partydrogen im Überblick 2026 | review | Unclear | Party drugs encompass a broad spectrum of substances with diverse pharmacological mechanisms, and cannabis is among the most commonly consumed. | |
| Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics". 2026 | qualitative study | 12 | Unclear | Healthcare providers' attitudes toward psychedelic-assisted therapy ranged from caution to advocacy, with substantial ethical, regulatory, and systemic constraints to clinical integration. |
| What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date. 2026 | narrative review | Mixed | Acute THC intoxication is associated with greater fronto-striatal brain activity, while regular cannabis users show lower hippocampal volume, altered white matter microstructure, and fronto-striatal neurochemical changes. | |
| Regional and cannabis-related differences in prefrontal multiscale entropy of resting-state EEG. 2026 | observational cohort | 57 | Opposes | Frequent cannabis users show a significantly flatter prefrontal cortex multiscale entropy slope, indicating reduced neural signal complexity at longer temporal scales. |
| Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol. 2026 | double-blind, placebo-controlled, randomized controlled trial | 60 | Unclear | The trial is ongoing; no results are reported in this abstract. |
| Cognitive performance recovery following marijuana cessation in NCAA division I athletes. 2026 | observational cohort | 18 | Opposes | Chronic THC use slows reaction speed by approximately 20% and degrades attention and control processes, with partial reversibility after 12 months of abstinence. |
THC selectively enhanced behavioral and neural responses to reward-predicting cues by amplifying mesocorticolimbic activity.
experimental study with within-subject design Sample size: 4
Psychological context ('set') is more strongly associated with psychedelic outcomes than substance type alone.
review
Cannabis-based medicines showed no clear evidence of providing clinically meaningful pain relief (≥50% reduction) compared with placebo, with low to very low certainty evidence.
systematic review with meta-analysis Sample size: 2187
Resting-state fNIRS detected THC-induced impairment with 90% accuracy and a 5% false-positive rate, significantly outperforming field sobriety tests.
double-blind, randomized, crossover trial Sample size: 183
THC (3 mg/kg) reduced nociception, body temperature, locomotor and exploratory activity, and acute motivation across genotypes, but chronic treatment did not affect motivation.
experimental study Sample size: 275
Policymakers should balance evidence, patient safeguards, and speed by supporting research, avoiding hindrances, improving pre-approval access, and preventing political FDA approvals.
review
Party drugs encompass a broad spectrum of substances with diverse pharmacological mechanisms, and cannabis is among the most commonly consumed.
review
Healthcare providers' attitudes toward psychedelic-assisted therapy ranged from caution to advocacy, with substantial ethical, regulatory, and systemic constraints to clinical integration.
qualitative study Sample size: 12
Acute THC intoxication is associated with greater fronto-striatal brain activity, while regular cannabis users show lower hippocampal volume, altered white matter microstructure, and fronto-striatal neurochemical changes.
narrative review
Frequent cannabis users show a significantly flatter prefrontal cortex multiscale entropy slope, indicating reduced neural signal complexity at longer temporal scales.
observational cohort Sample size: 57
The trial is ongoing; no results are reported in this abstract.
double-blind, placebo-controlled, randomized controlled trial Sample size: 60
Chronic THC use slows reaction speed by approximately 20% and degrades attention and control processes, with partial reversibility after 12 months of abstinence.
observational cohort Sample size: 18
Points of agreement
- Acute THC administration enhances activity in reward-related brain circuitry (mesocorticolimbic regions, fronto-striatal pathways).
- Chronic cannabis use is associated with reduced brain structure (hippocampal volume) and function (prefrontal signal complexity, cognitive performance).
- Cannabis-based medicines do not provide clinically meaningful pain relief for chronic neuropathic pain in adults.
Conflicts
- Acute THC enhances reward responsivity and brain activity, but chronic use is linked to cognitive deficits and reduced brain integrity.
- One review emphasizes psychological context over substance type for psychedelic outcomes, while other studies focus on substance-specific effects of THC.
- The systematic review on pain finds no clear benefit, whereas some preclinical studies show THC reduces nociception.
Gaps
- Durability of cognitive and neural changes after cannabis cessation is only partially studied (12-month follow-up in one small cohort).
- Blinding and placebo control are lacking in many observational studies; the large pain review notes low to very low certainty evidence.
- Populations studied are limited: mostly young adults, athletes, or animal models; generalizability to older adults or clinical populations is unclear.
- Dose-response relationships and long-term effects of different cannabis formulations (THC-dominant vs. CBD-dominant) are not well characterized.
- The ongoing PTSD trial (n=60) has not yet reported results, leaving therapeutic efficacy for PTSD unaddressed.